to determine how fully automated elecsys csf immunoassays for tau biomarkers
an ultrasensitive simoa assay for neurofilament light chain correlate with neuropathologic changes of disease lobar degeneration 
an ultrasensitive simoa assay for neurofilament light chain correlate with neuropathologic changes of frontotemporal lobar degeneration 
to determine how fully automated elecsys csf immunoassays for betaamyloid biomarkers
an ultrasensitive simoa assay for neurofilament light chain correlate with neuropathologic changes of frontotemporal lobar degeneration 
we studied 101 patients with neuropathology data
we studied 101 patients with antemortem csf
csf samples were collected a mean of 29 years before death
csf was analyzed for betaamyloid40 betaamyloid42 total tau tau
amino acid residue 181 tau phosphorylated at amino acid residue 181betaamyloid42 and betaamyloid42betaamyloid40 ratios and neurofilament light chain
tau phosphorylated at amino acid residue 181 tau
neuropathology measures included thal phases braak stages consortium to establish contributory pathologic diagnoses
neuropathology measures included thal phases braak stages consortium to establish alzheimer disease neuropathologic change
neuropathology measures included thal phases braak stages consortium to establish primary pathologic diagnoses
neuropathology measures included thal phases braak stages consortium to establish a registry for alzheimer disease scores
regression models alzheimer diseasejusted for time from sampling to death
regression models alzheimer diseasejusted for sex from sampling to death
associations between csf biomarkers were tested in regression models alzheimer
regression models alzheimer diseasejusted for age from sampling to death
associations between neuropathologic features were tested in regression models alzheimer
csf biomarkers were associated with neuropathologic measures of overall alzheimer disease neuropathologic change
csf biomarkers were associated with neuropathologic measures of tau
csf biomarkers were associated with neuropathologic measures of betaamyloid
tau phosphorylated at amino acid residue 181 total tau in frontotemporal lobar degenerationtar dnabinding protein
distinct biomarker patterns reduced total tau in progressive supranuclear palsy compared to other frontotemporal lobar degeneration variants
distinct biomarker patterns were seen in different frontotemporal lobar degeneration subtypes with increased neurofilament light chain and reduced tau 43
csf biomarkers including tau phosphorylated at amino acid residue neurofilament light chain support in vivo identification of alzheimer disease neuropathology
csf biomarkers including tau correlate with frontotemporal lobar degeneration neuropathology
csf biomarkers including tau phosphorylated at amino acid residue betaamyloid42 support in vivo identification of alzheimer disease neuropathology
csf biomarkers including tau phosphorylated at amino acid residue total tau support in vivo identification of alzheimer disease neuropathology
csf biomarkers including tau phosphorylated at amino acid residue 181 support in vivo identification of alzheimer disease neuropathology
csf biomarkers including tau phosphorylated at amino acid residue betaamyloid40 support in vivo identification of alzheimer disease neuropathology